Atea Pharmaceuticals (NASDAQ:AVIR – Get Free Report) and MIRA Pharmaceuticals (NASDAQ:MIRA – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.
Valuation and Earnings
This table compares Atea Pharmaceuticals and MIRA Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Atea Pharmaceuticals | N/A | N/A | -$168.38 million | ($1.77) | -2.66 |
| MIRA Pharmaceuticals | N/A | N/A | -$7.85 million | ($1.53) | -0.79 |
Institutional and Insider Ownership
86.7% of Atea Pharmaceuticals shares are held by institutional investors. Comparatively, 35.2% of MIRA Pharmaceuticals shares are held by institutional investors. 18.1% of Atea Pharmaceuticals shares are held by insiders. Comparatively, 6.7% of MIRA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Risk and Volatility
Atea Pharmaceuticals has a beta of 0.24, suggesting that its stock price is 76% less volatile than the S&P 500. Comparatively, MIRA Pharmaceuticals has a beta of 1.8, suggesting that its stock price is 80% more volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings and recommmendations for Atea Pharmaceuticals and MIRA Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Atea Pharmaceuticals | 1 | 1 | 1 | 1 | 2.50 |
| MIRA Pharmaceuticals | 1 | 0 | 1 | 0 | 2.00 |
Atea Pharmaceuticals presently has a consensus target price of $6.00, suggesting a potential upside of 27.25%. Given Atea Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts plainly believe Atea Pharmaceuticals is more favorable than MIRA Pharmaceuticals.
Profitability
This table compares Atea Pharmaceuticals and MIRA Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Atea Pharmaceuticals | N/A | -38.43% | -35.88% |
| MIRA Pharmaceuticals | N/A | -236.29% | -213.97% |
Summary
Atea Pharmaceuticals beats MIRA Pharmaceuticals on 7 of the 11 factors compared between the two stocks.
About Atea Pharmaceuticals
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
About MIRA Pharmaceuticals
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.
Receive News & Ratings for Atea Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atea Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
